Cargo Therapeutics (Cargo Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Change In Inventory?

Cargo Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Cargo Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Cargo Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Cargo Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Cargo Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cargo Therapeutics Change In Inventory Historical Data

The historical data trend for Cargo Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Change In Inventory Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Inventory

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial				-	-	-	-	-

Cargo Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cargo Therapeutics (NAS:CRGX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cargo Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cargo Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cargo Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Cargo Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics (Cargo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing strategy are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. Their lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics (Cargo Therapeutics) Headlines

From GuruFocus

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

By Marketwired • 04-15-2024